Medicare Expands Coverage for dd-cfDNA Testing, Boosting iMDx’s Commercial Strategy
Event summary
- Medicare’s final policy expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing, increasing reimbursement clarity for hospitals and laboratories.
- The new policy allows higher testing frequency for kidney and heart transplant patients compared to the draft policy.
- iMDx’s GraftAssure technology is cited in the policy, affirming its scientific leadership in the industry.
- Medicare reimbursement rate for GraftAssureCore is $2,753 per result, with plans to extend this rate to GraftAssureDx post-FDA approval.
The big picture
The Medicare policy supports iMDx’s strategy to enable in-house dd-cfDNA testing, aligning with industry trends toward decentralized diagnostic capabilities. The expanded coverage reinforces the value of dd-cfDNA testing in transplant care, potentially increasing patient access and improving clinical outcomes. This decision positions iMDx to capitalize on a $2 billion total addressable market for kitted transplanted organ testing.
What we're watching
- Regulatory Clarity
- How the expanded Medicare coverage will accelerate commercial adoption of iMDx’s GraftAssure assays.
- Market Expansion
- Whether the higher testing frequency will strengthen the economic case for transplant centers to bring dd-cfDNA testing in-house.
- FDA Approval Timing
- The pace at which iMDx can achieve FDA marketing authorization for GraftAssureDx, enabling broader market access.
Related topics